Evotec SE

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:35:46 2024-04-26 am EDT			5-day change	1st Jan Change
9.235 ^EUR	+0.82%		-30.35%	-56.60%

Apr. 26	EVOTEC : Deutsche Bank gives a Buy rating	ZD
Apr. 25	The specter of stagflation rears its ugly head again

EVOTEC : Jefferies remains its Buy rating

January 26, 2024 at 01:51 am EST

In a research note published by Peter Welford, Jefferies advises its customers to buy the stock. The target price is lowered from EUR 34 to EUR 28.

Latest news about Evotec SE

EVOTEC : Deutsche Bank gives a Buy rating	Apr. 26	ZD
The specter of stagflation rears its ugly head again	Apr. 25
EVOTEC : Buy rating from Deutsche Bank	Apr. 25	ZD
Top Midday Decliners	Apr. 24	MT
Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15	Apr. 24	DP
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	Apr. 24	MT
Transcript : Evotec SE, 2023 Earnings Call, Apr 24, 2024	Apr. 24
Technology Stocks Gain Amid Tesla's EV Plans as US Equity Futures Turn Mostly Higher Pre-Bell	Apr. 24	MT
Sector Update: Health Care	Apr. 24	MT
Top Premarket Decliners	Apr. 24	MT
RBC upgrades Evotec to 'Outperform' after figures and outlook	Apr. 24	DP
EVOTEC : Warburg Research reaffirms its Buy rating	Apr. 24	ZD
Jefferies rates Evotec a 'Buy' after figures and outlook	Apr. 24	DP
EVOTEC : Jefferies reaffirms its Buy rating	Apr. 24	ZD
EVOTEC : RBC keeps its Buy rating	Apr. 24	ZD
Evotec crashes - Too much uncertainty	Apr. 24	DP
Evotec SE Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
U.S. Futures, European Stocks Mixed	Apr. 24	DJ
Evotec under pressure - outlook disappointed	Apr. 24	DP
WDH/Evotec aims to return to profitable growth in 2024	Apr. 24	DP
Evotec aims to return to profitable growth in 2024	Apr. 24	DP
Evotec SE Provides Earnings Guidance for the Year 2024	Apr. 24	CI
Germany's Evotec Appoints Permanent CEO	Apr. 24	MT
Evotec Taps Christian Wojczewski as New CEO	Apr. 23	MT
Germany's Evotec appoints Christian Wojczewski as CEO	Apr. 23	RE

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - BofA Securities Health Care Conference

Related indices

STOXX EUROPE 600 (EUR) , MDAX

More about the company

Income Statement Evolution

More financial data

Ratings for Evotec SE

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.235 EUR

Average target price

24.7 EUR

Spread / Average Target

+167.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOTEC SE	-56.60%	1.75B
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

EVOTEC : Jefferies remains its Buy rating

Latest news about Evotec SE

Chart Evotec SE

Company Profile

Income Statement Evolution

Ratings for Evotec SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research